Breakthrough T1D Gala 2026 Celebrates Progress in Diabetes Research and Advocacy
Breakthrough T1D 2026 Gala: A Night of Hope and Advocacy
On November 18, 2026, the historic Plaza Hotel in New York City will host the 53rd Annual Breakthrough T1D Promise Gala, a hallmark event dedicated to raising awareness and funds for type 1 diabetes (T1D) research. This year's gala, organized by Breakthrough T1D, formerly known as JDRF, promises to be a powerful night filled with hope, community, and a commitment to advancing the lives of those affected by the condition.
The Promise Gala has raised over $85 million since its inception, supporting numerous initiatives aimed at finding cures and improving the daily lives of T1D patients. The evening will kick off at 6:00 PM with a cocktail reception, silent auction, and will be emceed by GRAMMY®-nominated musician Este Haim, who herself manages T1D. Her profound connection to the cause resonates as she shares her personal experiences of living with the disease, emphasizing the event's critical mission.
Este Haim expressed her sentiments leading up to the gala, stating, "Hosting the Breakthrough T1D Promise Gala is a chance to celebrate the T1D community and raise funds that will help push research toward cures for type 1 diabetes." Her passion for advocacy not only raises awareness but also unites attendees around a shared purpose: fighting against T1D and fostering scientific advancements.
Central to this year’s celebration is the recognition of Peter Hill, who will be honored as the Humanitarian of the Year. Hill, a senior managing director at Ramirez & Co. and a past president of the Breakthrough T1D New York City Chapter Board, has successfully raised over $2 million for the organization. His commitment is deeply personal, as several of his family members, including his daughter Sheila, live with T1D. Hill conveyed his appreciation, remarking, "Type 1 diabetes has touched my family personally, and that experience has strengthened my commitment to supporting the T1D community. I’m honored to be recognized by Breakthrough T1D."
An inspiring story shared during the event will be that of Katie Beth Hand, who participated in a Breakthrough T1D funded cell therapy clinical trial that has granted her independence from insulin. Her journey serves as a testament to the incredible possibilities that arise from philanthropic support for research initiatives. Hand stated, "After years of living with type 1 diabetes, achieving insulin independence through a clinical trial has given me freedom I never thought possible."
The gala is more than just a fundraising event; it embodies the hope and determination of the T1D community. With auction items, a live auction segment, and Breakthrough T1D's Fund A Cure program, which directs all contributions toward the organization’s mission, the atmosphere promises to be both celebratory and motivating.
Katie Schafer, the New York territory executive for Breakthrough T1D, remarked, "The Promise Gala brings the type 1 diabetes community together around a shared purpose: raising awareness, improving lives, and advancing research toward T1D cures."
As November is National Diabetes Awareness Month, this event shines a light on the realities of living with diabetes, celebrates the dedication of the community, and highlights the ongoing need for research and breakthroughs in treatment options.
As we approach the gala, we reflect on the shared commitment of those within the T1D community and their supporters, standing together in hope for a future where diabetes can be managed more effectively or even cured altogether.
About Breakthrough T1D:
Breakthrough T1D is a global advocacy organization dedicated to improving the lives of individuals with type 1 diabetes. Through research investment, education, and community support, the organization strives toward a future free from the burdens associated with the disease.
About Type 1 Diabetes:
Type 1 Diabetes is an autoimmune condition that drastically lowers insulin production, making ongoing management crucial for those diagnosed with it. This chronic disease affects nearly 9 million people worldwide and requires constant monitoring and management to prevent complications.
For media inquiries or more information, contact: Chelsea-Lyn Rudder, 646-946-0513, [email protected]